Please login to the form below

Not currently logged in
Email:
Password:

Nobel laureate Dr Walter Gilbert joins Amylyx Pharmaceuticals

He takes up a seat on the company's board of directors

Amylyx Dr Walter GilbertThe founder and former chief executive officer of Biogen Dr Walter Gilbert has been elected to Amylyx Pharmaceuticals' board of directors.

The US-based pharmaceutical firm specialises in developing disease-modifying treatments for neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS).

Justin Klee, co-founder and president of Amylyx, said: “Dr Gilbert brings an enormous breadth of experience as a scientist, biotech founder and executive.

“We are honoured that he will join our efforts to advance AMX0035 for the treatment of ALS, which will be tested in an initial clinical trial in patients later this year.”

Over his 40-year career in industry and academia, Dr Gilbert founded several life sciences companies, including Biogen where he was chief executive officer and chairman of the board between 1981 and 1985, and Myriad Genetics where he continues to serve as vice chairman of its board of directors.

Dr Gilbert received the Nobel Prize in Chemistry in 1980 for the development of a rapid method of DNA sequencing, and is currently the Carl M. Loeb University Professor Emeritus at Harvard University.

He said: “Amylyx has assembled an outstanding team that is advancing an innovative approach to ALS and other neurodegenerative diseases.

“I am excited to help bring this promising therapeutic to patients.”

26th January 2016

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

3 reasons why clinical trials will thrive in 2021
It’s not often that a single event can change the trajectory of an entire system, yet that is exactly what has happened to healthcare systems across the world and clinical...
#DemandDiversity: New research on COVID-19 clinical trial perceptions within minorities and high-risk populations
Lack of diversity in clinical trials still remains on of the biggest issues for COVID-19 clinical trials. But despite the growing discussions, calls for change, growing regulatory guidance and much...
Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...

Infographics